Cargando…

Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients

BACKGROUND: Breast cancer (BC) is a heterogeneous disease, and patients with apparently similar clinicopathological characteristics in clinical practice show different outcome. This study evaluated in primary BCs and in the subgroup of the triple-negative breast cancers (TNBCs) the level of tumor in...

Descripción completa

Detalles Bibliográficos
Autores principales: Schirosi, Laura, Saponaro, Concetta, Giotta, Francesco, Popescu, Ondina, Pastena, Maria Irene, Scarpi, Emanuela, Mangia, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931214/
https://www.ncbi.nlm.nih.gov/pubmed/31865181
http://dx.doi.org/10.1016/j.tranon.2019.10.020
_version_ 1783483049949790208
author Schirosi, Laura
Saponaro, Concetta
Giotta, Francesco
Popescu, Ondina
Pastena, Maria Irene
Scarpi, Emanuela
Mangia, Anita
author_facet Schirosi, Laura
Saponaro, Concetta
Giotta, Francesco
Popescu, Ondina
Pastena, Maria Irene
Scarpi, Emanuela
Mangia, Anita
author_sort Schirosi, Laura
collection PubMed
description BACKGROUND: Breast cancer (BC) is a heterogeneous disease, and patients with apparently similar clinicopathological characteristics in clinical practice show different outcome. This study evaluated in primary BCs and in the subgroup of the triple-negative breast cancers (TNBCs) the level of tumor infiltrating lymphocytes (TILs), Na(+)/H(+) exchanger regulatory factor 1 (NHERF1) expression, and their association respect to the clinical outcome of patients. MATERIAL AND METHODS: NHERF1 expression was assessed by immunohistochemistry in 338 BC samples; the analysis of TILs was examined using hematoxylin and eosin stained slides, according to International TILs Working Group 2014. RESULTS: Multivariate analysis identified TILs as an independent prognostic factor for DFS in the entire cohort and in the TNBC subgroup (HR, 0.32; 95% CI, 0.12–0.87; P = 0.026; and HR, 0.22; 95% CI, 0.06–0.80; P = 0.022, respectively). Univariate and survival analysis by Kaplan–Meier method revealed that patients with cytoplasmic (c) NHERF1(-)/TILs(+) expression had better DFS than other patients (P = 0.049), and this result was also found in the TNBC subgroup (P = 0.031). Moreover, TNBC patients with cNHERF1(−)/TILs(−) expression had a worse DFS and OS than other patients (P = 0.057 and P = 0.002, respectively). CONCLUSIONS: In the complex scenario of BC and in the era of tumor immunogenicity and immunotherapy, we found an association of TIL levels and cNHERF1 expression that could be useful to identify BCs and particularly TNBC patients with different prognosis and clinical outcome.
format Online
Article
Text
id pubmed-6931214
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-69312142019-12-30 Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients Schirosi, Laura Saponaro, Concetta Giotta, Francesco Popescu, Ondina Pastena, Maria Irene Scarpi, Emanuela Mangia, Anita Transl Oncol Original article BACKGROUND: Breast cancer (BC) is a heterogeneous disease, and patients with apparently similar clinicopathological characteristics in clinical practice show different outcome. This study evaluated in primary BCs and in the subgroup of the triple-negative breast cancers (TNBCs) the level of tumor infiltrating lymphocytes (TILs), Na(+)/H(+) exchanger regulatory factor 1 (NHERF1) expression, and their association respect to the clinical outcome of patients. MATERIAL AND METHODS: NHERF1 expression was assessed by immunohistochemistry in 338 BC samples; the analysis of TILs was examined using hematoxylin and eosin stained slides, according to International TILs Working Group 2014. RESULTS: Multivariate analysis identified TILs as an independent prognostic factor for DFS in the entire cohort and in the TNBC subgroup (HR, 0.32; 95% CI, 0.12–0.87; P = 0.026; and HR, 0.22; 95% CI, 0.06–0.80; P = 0.022, respectively). Univariate and survival analysis by Kaplan–Meier method revealed that patients with cytoplasmic (c) NHERF1(-)/TILs(+) expression had better DFS than other patients (P = 0.049), and this result was also found in the TNBC subgroup (P = 0.031). Moreover, TNBC patients with cNHERF1(−)/TILs(−) expression had a worse DFS and OS than other patients (P = 0.057 and P = 0.002, respectively). CONCLUSIONS: In the complex scenario of BC and in the era of tumor immunogenicity and immunotherapy, we found an association of TIL levels and cNHERF1 expression that could be useful to identify BCs and particularly TNBC patients with different prognosis and clinical outcome. Neoplasia Press 2019-12-19 /pmc/articles/PMC6931214/ /pubmed/31865181 http://dx.doi.org/10.1016/j.tranon.2019.10.020 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Schirosi, Laura
Saponaro, Concetta
Giotta, Francesco
Popescu, Ondina
Pastena, Maria Irene
Scarpi, Emanuela
Mangia, Anita
Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
title Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
title_full Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
title_fullStr Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
title_full_unstemmed Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
title_short Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
title_sort tumor infiltrating lymphocytes and nherf1 impact on prognosis of breast cancer patients
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931214/
https://www.ncbi.nlm.nih.gov/pubmed/31865181
http://dx.doi.org/10.1016/j.tranon.2019.10.020
work_keys_str_mv AT schirosilaura tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients
AT saponaroconcetta tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients
AT giottafrancesco tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients
AT popescuondina tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients
AT pastenamariairene tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients
AT scarpiemanuela tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients
AT mangiaanita tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients